European Commission approves Invega for treatment of schizophrenia in adolescents

Janssen-Cilag International’s Invega (paliperidone ER) has received the European Commission’s approval to extend its adult indication for treatment of schizophrenia to include adolescents aged 15 years and older.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news